Literature DB >> 2214609

Highly variable clinical course in severe alpha 1-antitrypsin deficiency--use of polymerase chain reaction for the detection of rare deficiency alleles.

W Poller1, J P Faber, K Olek.   

Abstract

Among 20 individuals with severe alpha 1-antitrypsin (alpha 1AT) deficiency we observed extremely variable clinical phenotypes ranging from rapidly progressive lung disease fatal at the age of 42 years to an asymptomatic individual with normal lung function at the age of 50 years. Eighteen subjects, including the asymptomatic one, carried the deficient Pi ZZ phenotype as determined by isoelectric focusing (IEF). Their mean alpha 1AT serum level was 36.7 +/- 7.7 mg/dl. DNA restriction analysis showed that all of them had the classical Pi Z-allele-associated DNA haplotype, thus confirming the IEF data. Obviously not all Pi ZZ individuals will have clinical sequelae caused by this genotype. The important differences in clinical course observed could not be explained by smoking habits alone. Probably additional factors are pertinent to the pathogenesis of the lung disease associated with alpha 1AT deficiency (defects in other genes, environmental influences other than smoking). In two patients with very low alpha 1AT serum levels definitive phenotyping by IEF was not possible. Therefore we investigated the molecular basis of their deficiency using polymerase chain reaction (PCR) amplification of the coding exons of their alpha 1AT genes and direct sequencing of the amplification products. Sequence data analysis showed that one of these patients, who had initially been phenotyped as Pi ZZ by IEF, had in fact the genotype Pi QObellinghamZ, thus explaining her low alpha 1AT serum level of 20 mg/dl. The other patient (alpha 1AT serum level 3.7 mg/dl) exhibited the rare genotype Pi MheerlenQOgranite falls. Despite his nearly complete alpha 1AT deficiency, he suffered from only moderately severe pulmonary disease at the age of 42 years.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2214609     DOI: 10.1007/bf01662782

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  23 in total

1.  Molecular characterisation of three alpha-1-antitrypsin deficiency variants: proteinase inhibitor (Pi) nullcardiff (Asp256----Val); PiMmalton (Phe51----deletion) and PiI (Arg39----Cys).

Authors:  A Graham; N A Kalsheker; C R Newton; F J Bamforth; S J Powell; A F Markham
Journal:  Hum Genet       Date:  1989-12       Impact factor: 4.132

2.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

3.  Variation in alpha-1-antitrypsin phenotypes associated with penicillamine therapy.

Authors:  D B Whitehouse; J U Lovegrove; D A Hopkinson
Journal:  Clin Chim Acta       Date:  1989-01-13       Impact factor: 3.786

4.  Smoking, lung function, and alpha 1-antitrypsin deficiency.

Authors:  E D Janus; N T Phillips; R W Carrell
Journal:  Lancet       Date:  1985-01-19       Impact factor: 79.321

5.  alpha 1-Antitrypsin nullGranite Falls, a nonexpressing alpha 1-antitrypsin gene associated with a frameshift to stop mutation in a coding exon.

Authors:  T Nukiwa; H Takahashi; M Brantly; M Courtney; R G Crystal
Journal:  J Biol Chem       Date:  1987-09-05       Impact factor: 5.157

6.  The effect of an acute phase response or pregnancy on plasma alpha-1-antitrypsin concentrations in persons with various S and Z phenotypes.

Authors:  A E Barr; D A Cole; A E Clague
Journal:  Ann Clin Biochem       Date:  1988-05       Impact factor: 2.057

7.  Identification of a second mutation in the protein-coding sequence of the Z type alpha 1-antitrypsin gene.

Authors:  T Nukiwa; K Satoh; M L Brantly; F Ogushi; G A Fells; M Courtney; R G Crystal
Journal:  J Biol Chem       Date:  1986-12-05       Impact factor: 5.157

8.  Prenatal diagnosis of alpha-1-antitrypsin deficiency using oligonucleotide probe analysis.

Authors:  C Meisen; M Higuchi; S Bräutigam; A J Driesel; M Blandfort; K Olek
Journal:  Hum Genet       Date:  1988-06       Impact factor: 4.132

9.  Emphysema of early onset associated with a complete deficiency of alpha-1-antitrypsin (null homozygotes).

Authors:  D W Cox; H Levison
Journal:  Am Rev Respir Dis       Date:  1988-02

10.  Emphysema associated with complete absence of alpha 1- antitrypsin in serum and the homozygous inheritance [corrected] of a stop codon in an alpha 1-antitrypsin-coding exon.

Authors:  K Satoh; T Nukiwa; M Brantly; R I Garver; M Hofker; M Courtney; R G Crystal
Journal:  Am J Hum Genet       Date:  1988-01       Impact factor: 11.025

View more
  5 in total

1.  DNA polymorphisms associated with a new alpha 1-antitrypsin PIQ0 variant (PIQ0riedenburg).

Authors:  W Poller; J P Faber; S Weidinger; K Olek
Journal:  Hum Genet       Date:  1991-03       Impact factor: 4.132

Review 2.  Genome-environment interactions in the molecular pathogenesis of dilated cardiomyopathy.

Authors:  W Poller; U Kühl; C Tschoepe; M Pauschinger; H Fechner; H-P Schultheiss
Journal:  J Mol Med (Berl)       Date:  2005-06-02       Impact factor: 4.599

3.  Identification and DNA sequence analysis of 15 new alpha 1-antitrypsin variants, including two PI*Q0 alleles and one deficient PI*M allele.

Authors:  J P Faber; W Poller; S Weidinger; M Kirchgesser; R Schwaab; F Bidlingmaier; K Olek
Journal:  Am J Hum Genet       Date:  1994-12       Impact factor: 11.025

4.  Clinical features and prognosis of life time non-smokers with severe alpha 1-antitrypsin deficiency.

Authors:  N Seersholm; A Kok-Jensen
Journal:  Thorax       Date:  1998-04       Impact factor: 9.139

Review 5.  Alpha 1-antitrypsin. Hope on the horizon for emphysema sufferers?

Authors:  M Schwaiblmair; C Vogelmeier
Journal:  Drugs Aging       Date:  1998-06       Impact factor: 3.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.